Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07804706

Preoperative Neutrophil-to-Albumin Ratio and Post-Induction Hemodynamic Vulnerability in Major Oncologic Surgery

This prospective observational study aims to evaluate whether the preoperative neutrophil percentage-to-albumin ratio (NPAR) is associated with post-induction hemodynamic vulnerability in adult patients undergoing elective major oncologic surgery under general anesthesia.

NPAR will be calculated from routine preoperative laboratory results by dividing the neutrophil percentage by the serum albumin level. No additional laboratory tests, medications, invasive procedures, or changes in anesthesia management will be performed for the purposes of the study.

Demographic characteristics, preoperative laboratory values, anesthetic data, and hemodynamic measurements will be recorded prospectively. Hemodynamic status will be evaluated during the period between induction of general anesthesia and surgical incision, with a maximum observation period of 20 minutes. Vasopressor use and administered doses will also be recorded.

The study will assess the ability of preoperative NPAR to identify patients who may be more susceptible to early hemodynamic instability following induction of general anesthesia.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Dr. Abdurrahman Yurtaslan Ankara Oncology Hospital

Ankara, Yeni̇mahalle, Turkey (Türkiye)

Location status: Recruiting

Location contact

Mustafa Kemal Şahin

CONTACT

[email protected]

+905075800976

About this study

This is a prospective, observational, non-interventional study involving adult patients undergoing elective major oncologic surgery under general anesthesia. The study is designed to evaluate the relationship between the preoperative neutrophil percentage-to-albumin ratio (NPAR) and post-induction hemodynamic vulnerability.

A total of 220 patients are planned to be enrolled using consecutive sampling. Eligible participants will be adults aged 18 years or older who are scheduled for elective major oncologic surgery under general anesthesia, have available preoperative complete blood count and serum albumin measurements, and undergo standard hemodynamic monitoring.

NPAR will be calculated by dividing the preoperative neutrophil percentage by the serum albumin concentration in g/dL. Demographic characteristics, ASA physical status, comorbidities, preoperative laboratory values, baseline hemodynamic measurements, induction-related data, intraoperative fluid administration, and vasopressor use and doses will be recorded prospectively.

Hemodynamic measurements will be evaluated from induction of general anesthesia until surgical incision, with a maximum observation period of 20 minutes. Participants will be classified according to the presence or absence of post-induction hemodynamic vulnerability.

The study will not alter routine anesthetic or surgical management. No additional medication, laboratory test, invasive procedure, or treatment modification will be performed for research purposes. Anesthetic agents, fluid therapy, and vasopressor administration will be determined by the responsible anesthesia team according to routine clinical practice.

The predictive performance of NPAR will be evaluated using receiver operating characteristic curve analysis and the area under the curve. Multivariable logistic regression analysis will be used to examine the association between NPAR and post-induction hemodynamic vulnerability while accounting for relevant clinical variables.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age 18 years or older
  • Scheduled for elective major oncologic surgery
  • Undergoing surgery under general anesthesia
  • Availability of preoperative complete blood count and serum albumin -measurements
  • Standard hemodynamic monitoring
  • Provision of written informed consent for participation in the study

Exclusion criteria

  • Age younger than 18 years
  • Emergency surgery
  • Preoperative hemodynamic instability
  • Preoperative vasopressor or inotropic support
  • Sepsis or active infection
  • Hematologic malignancy
  • Advanced cardiac, renal, or hepatic failure
  • Pregnancy
  • Missing preoperative laboratory data -Inability to complete the 20-minute post-induction evaluation period-

Treatment and study plan

Primary outcomes

  1. Occurrence of Post-Induction Hemodynamic Vulnerability

    Time frame: From induction of general anesthesia to surgical incision, up to 20 minutes

    Post-induction hemodynamic vulnerability will be defined as the occurrence of at least one mean arterial pressure (MAP) measurement ≤65 mmHg after induction of general anesthesia and before surgical incision. MAP will be assessed using standard intraoperative hemodynamic monitoring.

Study contacts

Contact information is provided by the study sponsor or research team.

Mustafa Kemal SAHIN, M.D

CONTACT

[email protected]

+5075800976

Sponsors and collaborators

Lead sponsor

Dr Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital

Other

Registry information

Official study title

Preoperative Neutrophil Percentage-to-Albumin Ratio as a Predictor of Post-Induction Hemodynamic Vulnerability in Major Oncologic Surgery

Important dates

Study start
2026
Primary completion
2026
Study completion
2026
First posted
Sep 4, 2026
Registry last updated
Sep 4, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.